A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck

Overview of attention for article published in Clinical Cancer Research, October 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

blogs: 1 blog

twitter: 13 X users

Readers on

mendeley: 14 Mendeley

So far, Altmetric has seen 14 X posts from 13 X users, with an upper bound of 23,591 followers.

Everolimus as Adjuvant Therapy in Advanced HNSCC Patients. https://t.co/2aVvrmVdl5 https://t.co/vfkcffKZix

p16-negative and TP53mut locally advanced SCCHN may benefit from adjuvant treatment with everolimus https://t.co/xPyU5EIbsB

RT @CCR_AACR: mTOR inhibitor #everolimus shows promising results in phase II trial as adjuvant therapy in patients with advanced head and n…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 10 additional X posts.